New progress has been made in the pharmacologically active ingredient of Lianhua Qing plague capsule against neocoopon pneumonia

Recently, Professor Wu Caisheng of Xiamen University School of Pharmacy, in cooperation with Professor Chai Yifeng of naval military medical university, made new progress in the study of the pharmacological active ingredients and mechanisms for the prevention and treatment of neo-crown pneumonia in Lianhua Qing plague capsules, and the results of the study "Anti-COVID-19 Pharmacological Active Ingredients based on Human Exposure and ACE2 Biochromatography Screening traditional Chinese medicine Lianhua Qing Plague Capsules" were published in pharmacology's top journal.
This study, based on HHRMS and intelligent non-targeting data mining techniques, comprehensively analyzed the components of lianhuasing plague capsules in human plasma and urine after multiple drug injections, synthesized the new ACE2 biochromatography fixed phase, and screened out potential ACE2 targeted components of lianhuasan plague capsule extracts and human urine samples. The experimental results showed that 85 related components of Lianhua Qing plague were successfully identified in the human body after multiple drug deliveries, and a small number of ingredients were selected to verify the binding ability of ACE2 through SPR analysis, and the components bitter almond glycoside, wild black sakuraside, glyphosate, ligand glycoside A, ligand glycoside I, jaundice, aloe vera jaundice, etc. all have binding affinity with ACE2. It is worth mentioning that these ingredients not only show good affinity to ACE2, but also confirmed by computer-aided docking results can be effectively combined on the contact surface of ACE2 and S protein complexes, these ACE2 binding ingredients may effectively affect the binding between ACE2 and S protein to inhibit the neo-coronavirus (SARS-CoV-2), for the prevention and treatment of colibulin capsule new crown pneumonia (COVID-19) provides an experimental basis.
Lianhua Qing plague capsule is based on the theory of traditional Chinese medicine, the collection of traditional classics and clinical practice developed innovative Chinese medicine, mainly used for cold, influenza, neo-crown pneumonia and other diseases of treatment. Since the outbreak of new coronary pneumonia, as one of the effective drugs screened out by Chinese medicine for the treatment of new crown pneumonia, Lianhua Qing plague capsules (particles) have been jointly issued by the National Health And Health Commission and the State Administration of Traditional Chinese Medicine, "New Coronavirus Pneumonia Diagnosis and Treatment Program" (trial 4/5) /6/7/8 edition) and more than 20 provinces and cities of the new coronary pneumonia diagnosis and treatment program recommended by the State Drug Administration approved for the "new coronavirus pneumonia light, ordinary type" treatment, in the treatment of patients with new coronary pneumonia played an important role in becoming a hot drug against the epidemic.
The research results published in this issue are the first elaboration of the research information on the composition of Lianhua Qing plague capsules in the human body, which provides a chemical and pharmacological theoretical basis for the study of its pharmacological active ingredients and mechanisms of action in the fight against neocycical coronary pneumonia (COVID-19), and further expounds how and what ingredients play a role in lianhua qing plague treatment.
Previously, research by the Zhong Nanshan
research team confirmed that lianhua-clear plague significantly inhibited the replication of new coronaviruses in cells, significantly reduced intracellular viral particle expression, and significantly inhibited the overexpression of genes from inflammatory factors TNF-a, IL-6, MCP-1 and IP-10 caused by new coronavirus infection cells. The study revealed the pharmacological basis of the exact efficacy of Lianhua Qing fever in neocytosis, and confirmed that Lianhua Qing plague plays an anti-neocytoviral activity by inhibiting viral replication and inhibiting the expression of host cell inflammatory factors.
On the basis of this research, lianhua qing plague capsule prevention and treatment of new coronary pneumonia pharmacological active ingredient research results, further elaborated lianhua qing plague by affecting S protein and cell binding to inhibit the new coronavirus invasion, in the existing cell level evidence deep molecular level once again confirmed the role of lianhua qing plague anti-neocytovirus.
During last year's outbreak of neo-crown pneumonia,
more than 20 hospitals in the country, including Zhong Nanshan, jointly conducted a "forward-looking, randomized, controlled, multi-center clinical study of the treatment of new coronavirus pneumonia in Chinese medicine, " the results of which were published in the international journal Phytomedicine, a journal with higher influence factors in the field of botany. The results showed that the application of Lianhua Qing plague capsules for 14 days could significantly improve the improvement rate of clinical symptoms such as fever, fatigue and cough, significantly improve lung imaging lesions, shorten the duration of symptoms, improve the rate of clinical cure, and curb the deterioration of neo crown disease.